ISSN: 2167-7700
Makoto Sumazaki and Fumi Saito
Triple negative breast cancer (TNBC) is an aggressive histological subtype with limited treatment options. While
rationally-derived regimens are emerging from the results of recent gene profiling studies, TNBC is an angiogenesisdependent
malignancy, and antiangiogenic therapies have been examined energetically in this field. Antiangiogenic
agents in combination with chemotherapeutic platinum compounds have shown some benefit in recent randomized
control studies for the treatment of TNBC. These combinations could be more safe and efficacious in patients, when
pharmacotherapy schedule is modified taking into account its tolerability.